A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a cohort study to evaluate safety and immunogenicity of COVID-19 mRNA Vaccine,
Bivalent (LVRNA021) in participants aged 18 years and over in China
Phase:
N/A
Details
Lead Sponsor:
AIM Vaccine Co., Ltd.
Collaborators:
First Affiliated Hospital Bengbu Medical College Ningbo Rongan Biological Pharmaceutical Co. Ltd